申请人:Nikken Chemicals Company, Limited
公开号:EP1055672A1
公开(公告)日:2000-11-29
A 1,4-dihydropyridine derivative having the formula (I):
wherein, R1 represents a substituted or unsubstituted phenyl or pyridyl group, R2 represents a C1 to C5 lower alkyl group, R3 represents a substituted or unsubstituted C1 to C8 alkyl, alkenyl, alkynyl or substituted or unsubstituted C3 to C7 cycloalkyl or cycloalkenyl group, R4 represents -A-R5, wherein A represents a C3 to C5 alkynylene group having one triple bond, and R5 represents a substituted or unsubstituted pyridyl, quinolyl, isoquinolyl or pyrimidyl group and a drug for overcoming resistance to an anti-cancer drug or a drug increasing the effect of an anti-cancer drug containing as an effective ingredient the derivative or its pharmacologically acceptable salt or hydrate.
具有式(I)的1,4-二氢吡啶衍生物:
其中,R1 代表取代或未取代的苯基或吡啶基,R2 代表 C1 至 C5 低级烷基,R3 代表取代或未取代的 C1 至 C8 烷基、烯基、炔基或取代或未取代的 C3 至 C7 环烷基或环 烯基,R4 代表-A-R5,其中 A 代表具有一个三键的 C3 至 C5 烯基、和 R5 代表取代或未取代的吡啶基、喹啉基、异喹啉基或嘧啶基,以及一种用于克服抗癌药物抗药性的药物或一种增加抗癌药物疗效的药物,其有效成分含有该衍生物或其药理学上可接受的盐或水合物。